William Sievert

Professor

Professor, Medicine Monash Health
Centre for Inflammatory Disease Monash Health

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor William Sievert is a clinician-scientist with dual appointments at Monash University and Monash Health as the Director of the Gastrointestinal and Liver Unit. Professor Sievert has a long-term interest in liver disease and directs an active clinical research unit comprising physician-scientists, clinical research nurses and research students.

The Clinical Research Unit has been continuously active over ten years and regularly contributes to international trials of new antiviral agents for hepatitis B and C in addition to developing and leading national investigator-initiated studies. He also directs a basic research laboratory investigating mechanisms of inflammatory liver injury and hepatic fibrogenesis, with a translational focus on identification and development of potential hepatic antifibrotic agents.

Professor Sievert is also active in medical education including the development of new undergraduate and graduate medical curricula at Monash University.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

2 Not started
7 Finished
11 Active

Engineering a solution to non-alcoholic steatohepatitis through tuning substrate stiffness

Lim, R., Sievert, W., Wallace, E., Frith, J., Greening, D. & Kusuma, G.

1/06/20 → 31/05/22

Project: Research

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma

Sievert, W.

24/01/20 → 23/01/25

Project: Research

A Phase 2a, randomized, double-blind, placebo-controlled study of oral FXR modulator EYP001a combined with nucleos(t)ide analogues (NA) in virologically suppressed chronic hepatitis B patients to improve functional cure rates

Sievert, W.

20/12/19 → 19/12/24

Project: Research

A Single and Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-729 Administered by Subcutaneous Injection to Healthy Subjects and Subjects with Chronic Hepatitis B Infection

Sievert, W.

16/10/19 → 15/10/24

Project: Research

Using smart technology to more effectively and efficiently monitor the quality of cancer care

Zalcberg, J., Evans, S., Bain, C., Aleti, A., Mac Manus, C., Brown, W., Sievert, W., Evans, P., Davis, I., Evans, M., Holland, J. & Brand, M.

Australian Government Department of Health

1/07/19 → 30/06/21

Project: Research

Research Output

100 Article
8 Letter
5 Chapter (Book)
3 Abstract
7 More

Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial

Yuen, M. F., Agarwal, K., Gane, E. J., Schwabe, C., Ahn, S. H., Kim, D. J., Lim, Y. S., Cheng, W., Sievert, W., Visvanathan, K., Ruby, E., Liaw, S., Yan, R., Huang, Q., Colonno, R. & Lopatin, U., 1 Feb 2020, In : The Lancet Gastroenterology & Hepatology. 5, 2, p. 152-166 15 p.